secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2024-10-18T23:59:59+00:00
Accession:  0000950170-24-115596
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics CSO Marc Van Dijk transitions to advisory roles effective Nov 15
--------------------------------------------------------------------------------

- Dr. Marc Van Dijk leaves Chief Scientific Officer role, becomes Scientific Advisory Board Member and Strategic Consultant.
- Transition effective November 15, 2024; Van Dijk to continue supporting programs and collaborations.
- No replacement for CSO announced; advisory roles indicate retained expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000095017024115596/0000950170-24-115596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000095017024115596/inkt-20241015.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-115596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer